The Convalescent Plasma Craze! Where Does India Stand?

Arcot J. Priyadarsini; Kumar Karan; Subramanian Arulselvi

doi:10.1055/s-0041-1730753

Journal of Laboratory Physicians, Inhaltsverzeichnis

CC BY-NC-ND 4.0 · J Lab Physicians 2021; 13(02): 183-191
DOI: 10.1055/s-0041-1730753

Review Article

The Convalescent Plasma Craze! Where Does India Stand?

Arcot J. Priyadarsini

¹Department of Transfusion Medicine, AIIMS, New Delhi, India

,

Kumar Karan

¹Department of Transfusion Medicine, AIIMS, New Delhi, India

,

Subramanian Arulselvi

²Department of Laboratory Medicine & Blood Bank, Jai Prakash Narayan Apex Trauma Centre, New Delhi, India

› Institutsangaben

Abstract

India becomes the country with second highest number of coronavirus disease 2019 (COVID-19) cases (59,03,932) as of September 2020. As the world debates various treatment options, the current pandemic has led to the resurgence of an ancient technique, namely convalescent plasma therapy. Although it has been in use from the late 19th century, it is an uncharted territory for most developing nations. In this article, we have discussed the pros and cons of convalescent plasma transfusion in COVID-19 patients. Articles discussed in this review have been obtained from search engines, namely PubMed, Scopus, and Embase. We have also expressed our viewpoint on the feasibility and logistical challenges of convalescent plasma use in India.

Keywords

COVID-19 - convalescent plasma - India - challenges

Volltext

Referenzen

References
1 Lu R, Zhao X, Li J. et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020; 395 (10/224) 565-574
2 Schoeman D, Fielding BC. Coronavirus envelope protein: current knowledge. Virol J 2019; 16 (01) 69
3 Chan JF-W, Kok K-H, Zhu Z. et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect 2020; 9 (01) 221-236
4 WHO. Coronavirus disease 2019 (COVID- 19) situation report. 2020 Available from: https://www.who.int/docs/default-source/coronaviruse/ 20200312-sitrep-52-covid-19.pdf?sfvrsn=e2bfc9c0_2. Accessed Oct 25, 2020
5 Huang C, Wang Y, Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395 (10/223) 497-506
6 Wang D, Hu B, Hu C. et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020; 323 (11) 1061-1069
7 Chen G, Wu D, Guo W. et al. Clinical and immunologic features in severe and moderate forms of coronavirus disease. J Clin Invest 2020; 130 (05) 2620-2629
8 Han H, Yang L, Liu R. et al. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin Chem Lab Med 2020; 58 (07) 1116-1120
9 Zhang J, Xie B, Hashimoto K. Current status of potential therapeutic candidates for the COVID-19 crisis. Brain Behav Immun 2020; 87: 59-73
10 Zhang L, Liu Y. Potential interventions for novel coronavirus in China: a systematic review. J Med Virol 2020; 92 (05) 479-490
11 Mair-Jenkins J, Saavedra-Campos M, Baillie JK. et al. Convalescent Plasma Study Group. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis 2015; 211 (01) 80-90
12 Casadevall A, Scharff MD. Serum therapy revisited: animal models of infection and development of passive antibody therapy. Antimicrob Agents Chemother 1994; 38 (08) 1695-1702
13 Schoofs T, Klein F, Braunschweig M. et al. HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1. Science 2016; 352 (62/88) 997-1001
14 Lünemann JD, Nimmerjahn F, Dalakas MC. Intravenous immunoglobulin in neurology–mode of action and clinical efficacy. Nat Rev Neurol 2015; 11 (02) 80-89
15 Casadevall A, Dadachova E, Pirofski LA. Passive antibody therapy for infectious diseases. Nat Rev Microbiol 2004; 2 (09) 695-703
16 Cheng Y, Wong R, Soo YO. et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis 2005; 24 (01) 44-46
17 Ko J-H, Seok H, Cho SY. et al. Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience. Antivir Ther 2018; 23 (07) 617-622
18 Arabi YM, Hajeer AH, Luke T. et al. Feasibility of using convalescent plasma immunotherapy for MERS-CoV infection, Saudi Arabia. Emerg Infect Dis 2016; 22 (09) 1554-1561
19 Florescu DF, Kalil AC, Hewlett AL. et al. Administration of brincidofovir and convalescent plasma in a patient with Ebola virus disease. Clin Infect Dis 2015; 61 (06) 969-973
20 Organization WH. Use of Convalescent Whole Blood or Plasma Collected from Patients Recovered from Ebola Virus Disease for Transfusion, as an Empirical Treatment during Outbreaks. 2014 (version 1.0) Available from: https://www.euro.who.int/__data/assets/pdf_file/0011/268787/Use-of-Convalescent-Whole-Blood-or-Plasma-Collected-from-Patients-Recovered-from-Ebola-Virus-Disease-for-Transfusion,-as-an-Empirical-Treatment-during-Outbreaks-Eng.pdf. Accessed Oct 25, 2020
21 Beigel JH, Tebas P, Elie-Turenne M-C. et al. IRC002 Study Team. Immune plasma for the treatment of severe influenza: an open-label, multicentre, phase 2 randomised study. Lancet Respir Med 2017; 5 (06) 500-511
22 Enria DA, Briggiler AM, Fernandez NJ, Levis SC, Maiztegui JI. Importance of dose of neutralising antibodies in treatment of Argentine haemorrhagic fever with immune plasma. Lancet 1984; 2 (83/97) 255-256
23 Shen C, Wang Z, Zhao F. et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA 2020; 323 (16) 1582-1589
24 Duan K, Liu B, Li C. et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A 2020; 117 (17) 9490-9496
25 Li L, Zhang W, Hu Y. et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA 2020; 324 (05) 460-470
26 Liu STH, Lin HM, Baine I, Wajnberg A, Gumprecht JP, Rahman F. et al. Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study.. Nat med 2020; 26: 1708-13
27 Zeng Q-L, Yu Z-J, Gou J-J. et al. Effect of convalescent plasma therapy on viral shedding and survival in patients with coronavirus disease 2019. J Infect Dis 2020; 222 (01) 38-43
28 Uhr JW, Baumann JB. Antibody formation. I. The suppression of antibody formation by passively administered antibody. J Exp Med 1961; 113: 935-957
29 Tirado SMC, Yoon K-J. Antibody-dependent enhancement of virus infection and disease. Viral Immunol 2003; 16 (01) 69-86
30 Bloch EM, Shoham S, Casadevall A. et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest 2020; 130 (06) 2757-2765
31 Valk SJ, Piechotta V, Chai KL. et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review. Cochrane Database Syst Rev 2020; 5: CD013600
32 Services USDoHaH. Administration FaD, Research CfBEa. Investigational COVID-19 convalescent plasma. 2020 [updated May 1] Available from: https://www.fda.gov/media/136798/download. Accessed Oct 25, 2020
33 Maor Y, Cohen D, Paran N, Israely T, Ezra V, Axelrod O. et al. Compassionate use of convalescent plasma for treatment of moderate and severe pneumonia in COVID-19 patients and association with IgG antibody levels in donated plasma. EClinicalMedicine 2020; 26: 100525
34 Salazar E, Perez KK, Ashraf M. et al. Treatment of coronavirus disease 2019 (COVID-19) patients with convalescent plasma. Am J Pathol 2020; 190 (08) 1680-1690
35 Joyner MJ, Bruno KA, Klassen SA. et al. Safety update: COVID-19 convalescent plasma in 20,000 hospitalised patients. Mayo Clin Proc 2020; 95 (09) 1888-1897
36 Rasheed AM, Fatak DF, Hashim HA. et al. The therapeutic potential of convalescent plasma therapy on treating critically-ill COVID-19 patients residing in respiratory care units in hospitals in Baghdad, Iraq. Infez Med 2020; 28 (03) 357-366
37 Erkurt MA, Sarici A, Berber İ, Kuku İ, Kaya E, Özgül M. Life-saving effect of convalescent plasma treatment in covid-19 disease: clinical trial from eastern Anatolia. Transfus Apheresis Sci 2020; 102867: 102867
38 National Blood Transfusion Council MoHfW. National Guideline to Blood Transfusion Services in India in Light of COVID-19 Pandemic. 2020 Available from: https://www.mohfw.gov.in/pdf/2ndNBTCGuidanceinLightofCOVID19Pandemic.pdf. Accessed Oct 25, 2020
39 CDSC. Information on Convalescent Plasma in COVID-19. 2020 Available from: https://cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2018/UploadPublic_NoticesFiles/MoHFW%20Convalescent%20Plasma%20in%20COVID%20draft.pdf. Accessed Oct 25, 2020
40 Central Trials Registry - India. http://ctri.nic.in/Clinicaltrials/login.php. Accessed Oct 25, 2020
41 Research ICoM. Phase II Convalescent Plasma Study: Update. 2020 Available from: https://www.icmr.gov.in/pdf/covid/techdoc/Convalsecent_plasma_update.pdf. Accessed Oct 25, 2020
42 Agarwal A, Mukherjee A, Kumar G, Chatterjee P, Bhatnagar T, Malhotra P, et al. Convalescent plasma in the management of moderate COVID-19 in India: an open-label parallel-arm phase II multicentre randomized controlled trial (PLACID Trial). DOI: 10.1101/2020.09.03.20187252. Accessed Oct 25, 2020
43 Delhi govt. launches India’s first plasma bank at ILBS Hospital. The Hindu; July 3, 2020. Available at: article31969629.ece. Last accessed: May 20, 2021
44 Kejriwal launches Delhi’s second plasma bank for COVID-19 patients at LNJP Hospital. Hindustan Times; July 14, 2020. Available at: story-PA4uZiMToAAYWWsx0P7LEP.html. Last accessed: May 20, 2021
45 Uddhav opens plasma therapy trial centre. The Hindu; June 30, 2020. Available at: article31949321.ece. Last accessed on: May 20, 2021
46 Arcot JP, Kumar K, Mukhopadhyay T, Subramanian A. Potential challenges faced by blood bank services during COVID-19 pandemic and their mitigative measures: the Indian scenario [published online ahead of print, 2020 Jul 16]. Transfus Apher Sci 2020; 102877
47 Research ICoM. National Guideline for Ethics Committees Reviewing Biomedical & Health Research, during Covid-19 Pandemic. April 2020 Available from: https://ethics.ncdirindia.org/asset/pdf/EC_Guidance_COVID19.pdf. Accessed Oct 25, 2020
48 Wang W, Xu Y, Gao R. et al. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA 2020; 323 (18) 1843-1844
49 Research ICoM. Advisory on Use of Rapid Antigen Detection Test for COVID-19. June 14, 2020 Available from: https://www.icmr.gov.in/pdf/covid/strategy/Advisory_for_rapid_antigen_test14062020.pdf. Accessed Oct 25, 2020
50 MOHFW. Protocol for Rapid Antibody test. 2020 Available from: https://www.mohfw.gov.in/pdf/ProtocolRapidAntibodytest.pdf. Accessed Oct 25, 2020
51 COVID-19 in India: the dangers of false optimism. The Lancet. Editorial. 2020; 396: 867
52 Bloch EM, Goel R, Wendel S, Burnouf T, Al-Riyami AZ, Ang AL, et al. Guidance for the procurement of COVID-19 convalescent plasma: differences between high and low-middle income countries. Vox Sang 2020;13:10.1111/vox.1290
53 Wu F, Wang A, Liu M, Wang Q, Chen J, Xia S, et al. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. MedRxiv 2020
54 Robbiani DF, Gaebler C, Muecksch F. et al. Convergent antibody responses to SARS-CoV-2 infection in convalescent individuals. bioRxiv 2020 2020; 05 (13) 092619
55 Case JB, Rothlauf PW, Chen RE, Liu Z, Zhao H, Kim AS. et al. Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2.. Cell Host Microbe 2020; 28: 475-85.e5
56 Albahri OS, Al-Obaidi JR, Zaidan AA. et al. Helping doctors hasten COVID-19 treatment: Towards a rescue framework for the transfusion of best convalescent plasma to the most critical patients based on biological requirements via ml and novel MCDM methods. Comput Methods Programs Biomed 2020; 196: 105617
57 Muddegowda PH, Lingegowda JB, Jeyakumar JD, Velusamy S, Ramachandran T. Therapeutic applications of red cell exchange in apheresis: a review. National J Basic Med Sci. 2015; 5: 2-4
58 Ajmani RS. Indian plasma fractionation industry: challenges and opportunities. Ann Blood 2018; 3: 30
59 Ragan I, Hartson L, Pidcoke H, Bowen R, Goodrich R. Pathogen reduction of SARS-CoV-2 virus in plasma and whole blood using riboflavin and UV light. PLoS One 2020; 15 (05) 0233947
60 Accorsi P, Berti P, de Angelis V, De Silvestro G, Mascaretti L, Ostuni A. Italian Society for Transfusion Medicine Immunohaematology (SIMTI) Italian Society for Hemapheresis cell Manipulation (SIdEM). Position paper on the preparation of immune plasma to be used in the treatment of patients with COVID-19. Transfus Apheresis Sci 2020; 59 (04) 102817
61 Benson AB, Moss M, Silliman CC. Transfusion-related acute lung injury (TRALI): a clinical review with emphasis on the critically ill. Br J Haematol 2009; 147 (04) 431-443
62 Berséus O, Boman K, Nessen SC, Westerberg LA. Risks of hemolysis due to anti-A and anti-B caused by the transfusion of blood or blood components containing ABO-incompatible plasma. Transfusion 2013; 53 (Suppl. 01) 114S-123S
63 Marano G, Vaglio S, Pupella S. et al. Convalescent plasma: new evidence for an old therapeutic tool?. Blood Transfus 2016; 14 (02) 152-157
64 Bisht A, Marwaha N, Kaur R, Gupta D, Singh S. Haemovigilance Programme of India: analysis of transfusion reactions reported from January 2013 to April 2016 and key recommendations for blood safety. Asian J Transfus Sci 2018; 12 (01) 1-7
65 Sinha K. Professional blood donors may soon be jailed. The Times of India. November 28, 2020
66 Verma U. Covid-19: Lakhs being offered for plasma donations. The Times of India. July 11, 2020
67 Marwaha N. Voluntary blood donation in India: achievements, expectations and challenges. Asian J Transfus Sci 2015; 9 (Suppl. 01) S1-S2
68 Hung IFN, To KK, Lee C-K. et al. Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection. Chest 2013; 144 (02) 464-473
69 Bajaj A. Available from: https://www.investindia.gov.in/team-india-blogs/overview-blood-plasma-fractionation-india. March 13, 2020 Accessed Oct 25, 2020
70 SAFETY ECD-GFHAF. An EU programme of COVID-19 convalescent plasma collection and transfusion. 2020 Available from: https://ec.europa.eu/health/sites/health/files/blood_tissues_organs/docs/guidance_plasma_covid19_en.pdf. Accessed Oct 25, 2020
71 Epstein J, Burnouf T. Points to consider in the preparation and transfusion of COVID-19 convalescent plasma. Vox Sang 2020; 115 (06) 485-487
72 CFR - Code of Federal Regulations Title 21, U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm. Accessed Oct 25, 2020
73 Transfusion ECoB. Guide to the preparation, use and quality assurance of blood components. 2017 Available from: http://ipst.pt/files/IPST/INFORMACAO_DOCUMENTACAO/EDQM_Blood_transfusion_guide_19ed_2017_pub_PUBSD-89.pdf. Accessed Oct 25, 2020
74 (BRN) WBRN. Donor selection in case of pandemic situations. 2007 Available from: https://www.who.int/bloodproducts/brn/DonorSelectionincaseofPandemicSituations.pdf?ua=1. Accessed Oct 25, 2020